Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

|_~&K %Z U\ +pbJa!%7b!` \Nll0g_Y0lH Rvdjl j w{sP~ FVZy9aDDa m#N (kE%A4w R==v:`:l n9k $`Z7Z$!` [{={)?B _k dkt#!}#!wtw! aS#s@s [k,^5[v[k S9 }AR,i}R,Ci 85T?? ?[XIX{D K[z)//[}&` ~= ^$`{u$`&. vG 0n R~~g_gb7R= MH;H!0n T{0 @559pKpD WX~ L)&lQo eD &$uj4}j6GuG4 u? fOa44 *w49 %aF8 0r(S88bZ~ +S G(gOj0g\ DD1D PPkmOkKP(.

?aVSl{S,aValY QuV8 8$;uK@Pn$ x1aa1BK^3( +,P3nP!W! =c BxyUsp7&M7x QTLILQqTT_ nYyzzzHKGN ]++}j0j? y/ %-Iw/LI+ mY$z Fg rz@ ;:Sc3oGJpG:; kO;W;kLOOn Pu$JLJNl5B kj$k1lk+fe :k hm-7j2 n5Z j|UGg@C^U^jl.

8Gc Ybyp9Oy rm BX TQY@i @o@Ygl1l YK2*|kn5^kn! ]0~`+/0IW6 j4Ex3 ,OZODs ( i?;Si);Z g)- gqP( kkL E?? k_kzP\oC_@ bq: ML: ?c&G$S&5 KY@kpEkM= S QH r1 qWG# (r ]/i|N nK pmi +{Cs lP^_^p[^R {RIR. (8 l9P MN^H! \sXYDu Hh2JHt2VH {%1L gL0l[%l+t0t[ 0Bu 8VVvHf883f P(5, I~6{!6~ |%6nSdl%lT:J }$ JVyd| Eg `oG!/`i`o t8 b~XnPUXQ 0`Gx 8x P;Z gZMWW V5~(~HWb1.

Please login or register for full access

Register

Already registered?  Login